Table 3 Sensitivity and specificity of pan-Trk immunohistochemistry for detecting NTRK fusions

From: NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

 

Sensitivity

 

NTRK1

96.2% (26/27)

 

NTRK2

100% (5/5)

 

NTRK3

79.4% (27/34)

 
 

Sensitivity

Specificity

Total

87.9% (58/66)

81.1% (257/317)

Colon

87.5% (7/8)

100% (25/25)

Lung

87.5% (7/8)

100% (24/24)

Thyroid

81.8% (9/11)

100% (27/27)

Salivary

88.9% (8/9)

52% (13/25)

Breast

80% (4/5)

82.1% (23/28)

Inflammatory myofibroblastic tumor

100% (3/3)

100% (5/5)

Sarcoma

80% (8/10)

74.4% (29/39)

Pancreas

(0/0)a

100% (20/20)

Appendix

100% (1/1)

100% (1/1)

Cholangio

100% (2/2)

100% (19/19)

Glioma

100% (6/6)

20.8% (5/24)

Melanoma

100% (3/3)

100% (17/17)

Neuroendocrine

(0/0)a

88.9% (8/9)

Small round cell tumorb

(0/0)

45.8% (11/24)

Otherc

(0/0)

100% (30/30)

  1. aThe NTRK fusion positive pancreatic adenocarcinoma and pancreatic neuroendocrine tumor cases were detected on cytology specimens, and no material remained available for immunohistochemical studies
  2. bSmall round cell tumors included embryonal rhabdomyosarcoma (8), neuroblastoma (5), Ewing sarcoma (5), desmoplastic small round cell tumor (5), and NUT midline carcinoma (1)
  3. cOther tumor types included prostatic adenocarcinoma (9), high-grade serous ovarian carcinoma (7), endometrioid adenocarcinoma (4), ampullary carcinoma (2), esophageal adenocarcinoma (2), esophageal squamous cell carcinoma (1), uterine perivascular epithelioid cell tumor (1), histiocytosis (1), myoepithelial carcinoma (1), granular cell tumor (1), and cancer of unknown primary (1)
Back to article page